If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
185
results.
Updated on
20/08/2026 [07:53:00]
Results 150 to 175 of 185
Absstract of: CN122297390A
The invention relates to a Vietnam camellia oleosa seed oil self-microemulsion preparation, a piperine self-microemulsion preparation taking Vietnam camellia oleosa seed oil as an oil phase as well as a preparation method and application of the piperine self-microemulsion preparation. The Vietnam camellia oleosa seed oil self-microemulsion preparation with an optimal prescription and the piperine self-microemulsion preparation taking the Vietnam camellia oleosa seed oil as the oil phase are prepared through prescription screening and optimization. An in-vitro cell experiment and an in-vivo pharmacodynamic experiment show that the Vietnam camellia oleosa seed oil self-microemulsion preparation has neuroprotective activity, can relieve nerve cell injury in a cerebral region of a Parkinson's disease model rat, can also improve dyskinesia of the Parkinson's disease model rat, and can increase the content of DA, DOPAC and HVA in injured side striatum of the Parkinson's disease model rat, so that the Vietnam camellia oleosa seed oil self-microemulsion preparation can be used for treating Parkinson's disease. After the piperine is combined with the piperine, the improvement effect of the piperine on the Parkinson's disease is enhanced, a good synergistic effect is shown, and a new treatment means is provided for treatment of the Parkinson's disease.
Absstract of: CN122303098A
The invention provides a lactobacillus plantarum HLP0106 and application of the lactobacillus plantarum HLP0106 or a fermentation product of the lactobacillus plantarum HLP0106 in prevention and/or treatment of Alzheimer's disease.
Absstract of: CN122277433A
The invention provides a compound with Parkinson's disease (PD) resisting activity, a source of the compound, a separation and purification method and application of the compound. According to the invention, the whole herb of snow lotus herb from Tianshan Mountain in Xinjiang is separated and purified to obtain a new compound 1 (Invoucramide). According to the present invention, the influence on the cell survival rate of the H2O2 induced damaged SH-SY5Y cell-PD model is adopted as the anti-PD activity evaluation index, such that the result shows that the survival rate of the H2O2 induced damaged SH-SY5Y cell can be significantly improved by using the compound invucramide, and the activity of the compound invucramide is better than the activity of the clinical first-line anti-PD drug rasagiline at the time of 20 M; the compound can be expected to be developed into a medicine for treating Parkinson's disease and other related neurodegenerative change diseases.
Absstract of: CN122272576A
The invention provides a kit, which comprises: (1) a pharmaceutical composition, the pharmaceutical composition comprising a therapeutically effective amount of harmine hydrochloride and a pharmaceutically acceptable carrier; and (2) a detection reagent for detecting vasoactive intestinal peptide (VIP) mRNA and/or protein. In the present invention, it is revealed for the first time that harmine hydrochloride (HH) has an extremely effective treatment effect on a specific parkinson's disease subject characterized by abnormal increase of vasoactive intestinal peptide (VIP), and the pharmaceutical composition and the kit of the present invention can specifically reduce the expression of pro-inflammatory VIP, and can be used in the treatment of Parkinson's disease. Further, a VIP-mediated microglial cell related neuroinflammation pathway is accurately intervened, so that the Parkinson's disease is remarkably treated, and a brand-new targeted therapy scheme is provided for clinical intervention of the Parkinson's disease.
Absstract of: CN122272741A
The invention discloses application of a traditional Chinese medicine composition in preparation of medicine, food or health care products for preventing and/or treating Alzheimer's disease and/or neuroinflammation and/or cognitive impairment, and the traditional Chinese medicine composition comprises hovenia dulcis thunb, mung beans, sea-buckthorn or fresh sea-buckthorn, pericarpium citri reticulatae, mulberry or fresh mulberry, turmeric and hawthorn. The traditional Chinese medicine composition has good prevention, treatment and improvement effects on Alzheimer's disease, neuroinflammation improvement and cognitive impairment alleviation, can effectively avoid toxic effects of acetaldehyde on human bodies, and realizes drunkenness prevention, rapid hangover alleviation and sobering up, and is safe and reliable. The traditional Chinese medicine composition has a good improvement effect on alcoholic liver injury, alcoholic stomach injury, alcoholic kidney injury, alcoholic brain injury, alcoholic cardiomyopathy and cognitive impairment caused by alcohol, also has the effects of protecting heart and cerebral vessels, tonifying spleen, protecting stomach and protecting liver, and has the advantages of small number of medicines, low cost, convenience in taking, no obvious toxic or side effect, convenience in daily carrying, and no toxic or side effect. And the beverage is suitable for timely taking by people for dispelling effects of alcohol, has prevention and health care effec
Absstract of: WO2026130309A1
A potassium channel gene treatment method for treating Parkinson's disease. A recombinant adeno-associated virus (AAV) nucleotide sequence comprises a nucleotide sequence encoding an inwardly rectifying potassium channel Kir. An AAV vector is used to deliver an inwardly rectifying potassium channel (Kir) gene to the subthalamic nucleus, such that excitability of neurons of the subthalamic nucleus is reduced, so as to alleviate symptoms such as motor deficits caused by excessive excitation of the subthalamic nucleus in patients with Parkinson's disease.
Absstract of: AU2023477048A1
The present invention relates to pharmaceutical compositions and medicaments comprising the compound of formula (I); or a stereoisomer, tautomer, pharmaceutically usable solvate or salt thereof, and dosage regimens for the administration thereof to human patients.
Absstract of: AU2024406255A1
Compositions and methods are disclosed herein for the treatment of Alzheimer's disease with allogeneic mesenchymal stem cells. The methods of treatment involve the administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the efficacy of the treatment methods can be determined through the measurement of specific biomarkers and improved cognitive function and/or quality of life.
Absstract of: US20260174724A1
0000 A composition for preventing and/or improving brain dysfunction, especially Alzheimer's disease is provided. The composition includes dihydromyricetin or salts thereof, L-theanine, taurine, and cerebroside, which can enhance the intestinal stability and bioavailability of dihydromyricetin and prevent and improve brain dysfunction through multiple mechanisms such as anti-inflammation, inhibition of DNA methylation, elimination of hematoma, and removal of Aβ. In addition, the composition can be used in combination with monoclonal antibody drugs to reduce adverse reactions such as cerebral edema and cerebral hemorrhage that may occur during the treatment of Alzheimer's disease.
Absstract of: US20260176633A1
Aspects of the disclosure relate to compositions and methods useful for treating Huntington's disease. In some embodiments, the disclosure provides interfering nucleic acids (e.g., artificial miRNAs) targeting the huntingtin gene (HTT) and methods of treating Huntington's disease using the same.
Absstract of: US20260174728A1
An orally administered composition positively mitigates the progression of central nervous system diseases such as Alzheimer's, Parkinson's and Multiple Sclerosis. The composition consists of a lipid based blood brain barrier transport medium (Base Transport Sub-Formula) to which other elements (Functional Targeting Compound) may be integrated to mediate specific chemo-neurological dysfunction. It may be administered through the mouth as droplets a spray medium or a chewable tablet.
Absstract of: US20260174808A1
The present invention relates to a composition for preventing, ameliorating or treating cognitive dysfunction or Alzheimer's disease comprising, as an active ingredient, Lactobacillus fermentum SRK414 strain which has accession number KCTC13687BP. The strain of the present invention is excellent in reducing barrier permeability and reducing amyloid beta and tau proteins and has an excellent effect in improving cognitive function, and accordingly, the strain can be useful for a food and therapeutic agent for same purposes.
Absstract of: US20260176315A1
Use of an interleukin 27 (IL-27) protein in preparation of a product for treating and/or delaying Alzheimer's disease (AD) is provided, belonging to the technical field of biomedicine. The IL-27 protein refers to a recombinant IL-27 protein targeting a therapeutic target IL-27, and is selected from the group consisting of a mouse-derived IL-27 protein and a human-derived IL-27 protein, as well as a mammalian IL-27 protein other than the mouse-derived IL-27 protein and the human-derived IL-27 protein. The recombinant IL-27 protein can effectively alleviate the AD caused by Aβ deposition, and can selectively bind to a target receptor, thereby ensuring an accuracy of test results. The protein receptor is highly expressed in the dentate gyrus region of hippocampus, and guarantees drug targeting to the greatest extent.
Absstract of: AU2024399699A1
SnRNA systems targeting SOD1 RNA sequences are disclosed herein. Further disclosed are methods of treating Amyotrophic Lateral Sclerosis.
Absstract of: WO2026136813A1
Disclosed herein is a polynucleotide comprising two or more siRNAs linked together with a single stranded nucleic acid. The two or more siRNAs may bind the same or bind different genes and may comprise a long passenger strand that is annealed to two or more guide strands with gaps of single stranded nucleic acids in between each duplex. Also disclosed herein a method of treating a disease or disorder comprising administering to a subject in need thereof a polynucleotide that targets genes associated with the disorder. The disease may include Alzheimer's disease.
Absstract of: US20260174945A1
0000 Patients suffering from, or at risk of developing the symptoms of, Alzheimer's disease and related neuroinflammatory-based diseases, are treated by apheresis to selectively withdrawal Galectin-3 from the patient's body. A reduction in the circulating level of gal-3 of the patient of at least 30% of the patient's pre-treatment galectin-3 level should be sufficient to reduce AD symptoms, and/or inhibit AD progression. A greater withdrawal, up to at least 20%, has greater impact. Selective withdrawal of Galectin-3 may be coupled with the administration of MCP to further slow the progress of, and/or reverse, AD symptoms.
Absstract of: WO2026136421A2
The present disclosure provides anti-ac-tauK174 antibodies, or antigen-binding fragments thereof. In addition, methods of using the anti-ac-tauK174 antibodies, or antigen-binding fragments thereof, for the treatment of the progression of and/or prevention of Alzheimer's Disease and related tauopathies, including traumatic brain injury, are also provided. Methods of reducing clinical decline in a subject having early Alzheimer's Disease, reducing brain amyloid levels in a subject, and methods of preventing Alzheimer's Disease and related tauopathies are also provided, the methods comprising administering a composition comprising a therapeutically effective amount of at least one anti-ac-tauK174 antibody. In some embodiments, the subject is ApoE4-positive.
Absstract of: WO2026135697A1
Patients suffering from, or at risk of developing the symptoms of, Alzheimer's disease and related neuroinflammatory-based diseases, are treated by apheresis to selectively withdrawal Galectin-3 from the patient's body. A reduction in the circulating level of gal-3 of the patient of at least 30% of the patient's pre-treatment galectin-3 level should be sufficient to reduce AD symptoms, and/or inhibit AD progression. A greater withdrawal, up to at least 20%, has greater impact. Selective withdrawal of Galectin-3 may be coupled with the administration of MCP to further slow the progress of, and/or reverse, AD symptoms.
Absstract of: EP4763972A1
0001 Provided are an Akkermansia muciniphila strain, and a product and a use thereof. The Akkermansia muciniphila strain is AKK PROBlO, and the preservation number thereof is CGMCC No. 20955, The AKK PROBIO has good tolerance, high safety, a wide range of indications and a good treatment effect, and can prevent and treat diseases such as colitis. colorectal cancer. Alzheimer's disease, and gouty arthritis.
Absstract of: EP4763164A2
0001 The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith.
Absstract of: WO2025038979A1
Material compositions and/or methods useful for the prophylaxis and/or treatment of protein depletion (proteinopenia) are provided, including material compositions that retains native function of a peptide/protein while limiting and/or preventing amyloid formation and/or aggregation of said peptide/protein. Material compositions and formulations for enhancing peptide/protein solubility, stability, circulation time, receptor interaction, brain penetrance, CSF half-life, facilitating peptide/protein synthesis and purification are also provided.
Absstract of: MX2026001933A
The present invention relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of cGAS, yet more in particular for the prevention or treatment of inflammation conditions or cancer. The present invention also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds as well as to said compositions or preparations for use as a medicine, more preferably for the prevention or treatment of diseases mediated by activity of cGAS, yet more in particular for the prevention or treatment of inflammation conditions or cancer. The present invention also relates to processes for the preparation of said compounds.
Absstract of: WO2025038863A1
Disclosed is a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof. The variables in Formula (I) are defined herein. Compounds of Formula (I) are useful for regulating GPR17 activity and for treating disorders and diseases mediated by GPR17 in humans or non-humans.
Nº publicación: EP4763834A2 24/06/2026
Applicant:
VIRGINIA TECH INTELLECTUAL PROPERTIES INC [US]
Virginia Tech Intellectual Properties, Inc.
Absstract of: EP4763834A2
The disclosure provide compounds of Formula Iand the pharmaceutically acceptable salts thereof. The variables, R1, R2, R3, X1, X2, and Z are defined herein. Certain compounds of Formula I act as selective mitochondrial protonophore uncouplers that do not affect the plasma membrane potential. Compounds and salts of Formula I are useful for treating or decreasing the risk of conditions responsive to mitochondrial uncoupling, such as cancer, obesity, type II diabetes, fatty liver disease, insulin resistance, Parkinson's disease, ischemia reperfusion injury, heart failure, non-alcoholic fatty liver disease (NALFD), and non-alcoholic steatohepatitis (NASH). Because mitochondrial uncouplers decrease the production of reactive oxygen species (ROS), which are known to contribute to age-related cell damage, compounds of Formula I are useful for increasing lifespan. Compounds and salts of Formula I are also useful for regulating glucose homeostasis or insulin action in a patient.
BOPI
Electronic site
